Oxidized low-density lipoprotein inhibits endothelium-dependent vasodilation by an antioxidant-sensitive, lysophosphatidylcholine-independent mechanism

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 6, 2003, Pages 856-865

  Chan, Holman ^a   Lougheed, Marilee ^a   Laher, Ismail ^a   Steinbrecher, Urs P ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Division of Gastroenterology   (Canada)

Author keywords

BO 653; Endothelium dependent relaxation; Endothelium derived vasodilation; Lysophosphatidylcholine; Oxidized LDL; Probucol; Vitamin E

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; ANTIOXIDANT; CALPHOSTIN C; LIPID PEROXIDE; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROBUCOL; PROTEIN KINASE C; SODIUM BOROHYDRIDE; SUPEROXIDE DISMUTASE;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL TONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME RELEASE; MESENTERIC ARTERY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; VASODILATATION;

ACETYLCHOLINE; ANIMALS; ANTIOXIDANTS; BOROHYDRIDES; CATALASE; ENDOTHELIUM, VASCULAR; FREE RADICAL SCAVENGERS; LIPOPROTEINS, LDL; LYSOPHOSPHATIDYLCHOLINES; MESENTERIC ARTERIES; NITROPRUSSIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHOLIPASES A; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; VASODILATION; VASODILATOR AGENTS;

EID: 0038795328     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200306000-00005     Document Type: Article

References (79)

1. Haberland M, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988; 241:215-8.
2. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989; 86:1372-6.
3. Rosenfeld ME, Palinski W, Ylä-Herttuala S, et al. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990; 10:336-49.
4. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-95.
5. Holvoet P, Perez G, Zhao Z, et al. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest. 1995; 95:2611-9.
6. Suarna C, Dean R, May J, et al. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of α-tococopherol and ascorbate. Arterioscler Thromb Vasc Biol. 1995;15:1616-24.
7. Kuhn H, Belkner J, Wiesner R, et al. Structure elucidation of oxygenated lipids in human atherosclerotic lesions. Eicosanoids. 1992;5:17-22.
8. Rimm E, Stampfer M, Asherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-6.
9. Stampfer M, Hennekens C, Manson J, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-9.
10. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987;84:7725-9.
11. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987; 84:5928-31.
12. Daugherty A, Zweifel BS, Schonfeld G. Probucol attenuates the development of atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol. 1989; 98:612-8.
13. Björkhem I, Henriksson-Freyschuss A, Breuer O, et al. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb. 1991;11:15-22.
14. Sparrow CP, Doebber TW, Olszewski J, et al. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′-diphenylphenylenediamine. J Clin Invest. 1992;89:1885-91.
15. Cynshi O, Kawabe Y, Suzuki T, et al. Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc Natl Acad Sci U S A. 1998;95:10123-8.
16. Palinski W, Ord V, Plump A, et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 1994;14:605-16.
17. Horkko S, Miller E, Branch DW, et al. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc Natl Acad Sci U S A. 1997;94:10356-61.
18. Bui M, Sack M, Moutsatsos G, et al. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J. 1996;131:663-7.
19. Berliner J, Heinecke J. The role of oxidized lipoproteins in atherogenesis. Free Radical Biol Med. 1996;20:707-27.
20. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-6.
21. Kugiyama K, Kerns SA, Morrisett JD, et al. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 1990;344:160-2.
22. Tanner FC, Noll G, Boulanger CM, et al. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries: role of scavenger receptor and endothelium-derived nitric oxide. Circulation. 1991;83:2012-20.
23. Kugiyama K, Ohgushi M, Sugiyama S, et al. Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res. 1992;71:1422-8.
24. Mangin EJ, Kugiyama K, Nguy JH, et al. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res. 1993;72:161-6.
25. Galle J, Mülsch A, Busse R, et al. Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium-derived relaxing factor. Arteriosclerosis. 1991;11:198-203.
26. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest. 1992;89:10-8.
27. 2(-) formation. Nephrol Dial Transplant. 2000;15:339-46.
28. Cominacini L, Rigoni A, Pasini AF, et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem. 2001;276:13750-5.
29. Blair A, Shaul PW, Yuhanna IS, et al. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999;274:32512-9.
30. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-9.
31. Zhao B, Ehringer WD, Dierichs R, et al. Oxidized low-density lipoprotein increases endothelial intracellular calcium and alters cytoskeletal F-actin distribution. Eur J Clin Invest. 1997;27:48-54.
32. Eizawa H, Yui Y, Inoue R, et al. Lysophosphatidylcholine inhibits endothelium-dependent hyperpolarization and N-omega-nitro-L-arginine/indomethacin-resistant endothelium-dependent relaxation in the porcine coronary artery. Circulation. 1995;92:3520-6.
33. Jacobs M, Plane F, Bruckdorfer KR. Native and oxidized low-density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta. Br J Pharmacol. 1990;100:21-6.
34. Schmidt K, Graier WF, Kostner GM, et al. Oxidized low-density lipoprotein antagonizes the activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor but does not interfere with its biosynthesis. Cell Signal. 1991;3:361-7.
35. Galle J, Lückhoff A, Busse R, et al. Low-density lipoproteins stimulate internal free calcium and prostacyclin release in endothelial cells. Eicosanoids. 1990;3:81-6.
36. Boulanger CM, Tanner FC, Bea ML, et al. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 1992;70:1191-7.
37. Horio T, Kohno M, Yasunari K, et al. Stimulation of endothelin-1 release by low density and very low density lipoproteins in cultured human endothelial cells. Atherosclerosis. 1993;101:185-90.
38. Jougasaki M, Kugiyama K, Saito Y, et al. Suppression of endothelin-1 secretion by lysophosphatidylcholine in oxidized low density lipoprotein in cultured vascular endothelial cells. Circ Res. 1992;71:614-9.
39. He Y, Kwan W, Steinbrecher U. Effects of oxidized low density lipoprotein on endothelin secretion by cultured endothelial cells and macrophages. Atherosclerosis. 1996;119:107-18.
40. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999;31:51-60.
41. Keaney J Jr, Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis. 1995;38:129-54.
42. Diaz MN, Frei B, Vita JA, et al. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997;337:408-16.
43. Gokce N, Keaney JF Jr, Frei B, et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1999;99:3234-40.
44. Keaney J Jr, Guo Y, Cunningham D, et al. Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J Clin Invest. 1996;98:386-94.
45. Steinbrecher UP, Parthasarathy S, Leake DS, et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883-7.
46. Steinbrecher UP, Pritchard PH. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res. 1989;30:305-15.
47. Ohgushi M, Kugiyama K, Fukunaga K, et al. Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modified LDL. Arterioscler Thromb. 1993;13:1525-32.
48. Cowan C, Steffen R. Lysophosphatidylcholine inhibits relaxation of rabbit abdominal aorta mediated by endothelium-derived nitric oxide and endothelium-derived hyperpolarizing factor independent of protein kinase C activation. Arterioscler Thromb Vasc Biol. 1995;15:2290-7.
49. Kikuta K, Sawamura T, Miwa S, et al. High-affinity arginine transport of bovine aortic endothelial cells is impaired by lysophosphatidylcholine. Circ Res. 1998;83:1088-96.
50. Plane F, Bruckdorfer KR, Kerr P, et al. Oxidative modification of low-density lipoproteins and the inhibition of relaxations mediated by endothelium-derived nitric oxide in rabbit aorta. Br J Pharmacol. 1992; 105:216-22.
51. Ota Y, Kugiyama K, Sugiyama S, et al. Complexes of apoA-1 with phosphatidylcholine suppress dysregulation of arterial tone by oxidized LDL. Am J Physiol. 1997;273:H1215-22.
52. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;43:1345-53.
53. Steinbrecher UP. Oxidation of human low density lipoproteins results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem. 1987;262:3603-8.
54. Quinn MT, Parthasarathy S, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987;84:2995-8.
55. Martens J, Lougheed M, Gomez-Muñoz A, et al. A modification of apolipoprotein B accounts for most of the induction of macrophage growth by oxidized low density lipoprotein. J Biol Chem. 1999;274:10903-10.
56. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-75.
57. Steinbrecher UP, Witztum JL, Parthasarathy S, et al. Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL: correlation with changes in receptor-mediated catabolism. A rteriosclerosis. 1987;7:135-43.
58. Noguchi N, Okimoto Y, Tsuchiya J, et al. Inhibition of oxidation of low-density lipoprotein by a novel antioxidant, BO-653, prepared by theoretical design. Arch Biochem Biophys. 1997;347:141-7.
59. Noguchi N, Iwaki Y, Takahashi M, et al. 2,3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: design and evaluation as a novel radical-scavenging antioxidant against lipid peroxidation. Arch Biochem Biophys. 1997;342:236-43.
60. Ingold K, Bowry V, Stocker R, et al. Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proc Natl Acad Sci U S A. 1993;90:45-9.
61. Steinbrecher UP, Lougheed M, Kwan WC, et al. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J Biol Chem. 1989;264:15216-23.
62. Lougheed M, Ming Lum C, Ling W, et al. High-affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/II. J Biol Chem. 1997;272:12938-44,
63. Kugiyama K, Sakamoto T, Misumi I, et al. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res. 1993;73:335-43.
64. Doi H, Kugiyama K, Ohgushi M, et al. Membrane active lipids in remnant lipoproteins cause impairment of endothelium-dependent vasorelaxation. Arterioscler Thromb Vasc Biol. 1999;19:1918-24.
65. Yokoyama M, Hirata K, Miyake R, et al. Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasoregulation by oxidized low-density lipoprotein. Biochem Biophys Res Commun. 1990; 168:301-8.
66. Leung SW, Teoh H, Quan A, et al. Endothelial dysfunction exacerbates the impairment of relaxation by lysophosphatidylcholine in porcine coronary artery. Clin Exp Pharmacol Physiol. 1997;24:984-6.
67. Kakutani M, Masaki T, Sawamura T. A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. Proc Natl Acad Sci U S A. 2000;97:360-4.
68. Moriwaki H, Kume N, Sawamura T, et al. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol. 1998;18:1541-7.
69. Sugiyama S, Kugiyama K, Ohgushi M, et al. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries: role of protein kinase C. Circ Res. 1994;74:565-75.
70. Sugiyama S, Kugiyama K, Ogata N, et al. Biphasic regulation of transcription factor nuclear factor-kappaB activity in human endothelial cells by lysophosphatidylcholine through protein kinase C-mediated pathway. Arterioscl Thromb Vasc Biol. 1998;18568-76.
71. Liu K, Massaeli H, Pierce GN. The action of oxidized low density lipoprotein on calcium transients in isolated rabbit cardiomyocytes. J Biol Chem. 1993;268:4145-51.
72. Cynshi O, Takashima Y, Katoh Y, et al. Action of phenolic antioxidants on various active oxygen species. J Biolumin Chemilumin. 1995;10:261-9.
73. Keaney J, Xu A, Cunningham D, et al. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest. 1995;95:2520-9.
74. Tasinato A, Boscoboinik D, Bartoli GM, et al. d-alpha-tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Proc Natl Acad Sci U S A. 1995;92:12190-4.
75. Ricciarelli R, Tasinato A, Clement S, et al. alpha-Tocopherol specifically inactivates cellular protein kinase C alpha by changing its phosphorylation state. Biochem J. 1998;334:243-9.
76. Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 1996;93:1647-50.
77. Keaney JF, Gaziano JM, Xu AM, et al. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc Natl Acad Sci U S A. 1993;90:11880-4.
78. Matz J, Andersson T, Ferns G, et al. Dietary vitamin E increases the resistance to lipoprotein oxidation and attenuates endothelial dysfunction in the cholesterol-fed rabbit. Atherosclerosis. 1994;110:241-9.
79. Kugiyama K, Sugiyama S, Soejima H, et al. Increase in plasma levels of oxidized low-density lipoproteins in patients with coronary spastic angina. Atherosclerosis. 2001;154:463-7.